DK1236711T3 - Anvendelse af allosteriske hæmoglobinmodifikatiorer til reducering af oxygenaffinitet i blod - Google Patents

Anvendelse af allosteriske hæmoglobinmodifikatiorer til reducering af oxygenaffinitet i blod

Info

Publication number
DK1236711T3
DK1236711T3 DK02012781T DK02012781T DK1236711T3 DK 1236711 T3 DK1236711 T3 DK 1236711T3 DK 02012781 T DK02012781 T DK 02012781T DK 02012781 T DK02012781 T DK 02012781T DK 1236711 T3 DK1236711 T3 DK 1236711T3
Authority
DK
Denmark
Prior art keywords
blood
oxygen affinity
reduce oxygen
allosteric hemoglobin
compound
Prior art date
Application number
DK02012781T
Other languages
English (en)
Inventor
Ramnarayan Randad
Donald J Abraham
Mona Mahran
Ahmed Mehanna
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/702,947 external-priority patent/US5122539A/en
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Application granted granted Critical
Publication of DK1236711T3 publication Critical patent/DK1236711T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK02012781T 1991-05-20 1992-05-19 Anvendelse af allosteriske hæmoglobinmodifikatiorer til reducering af oxygenaffinitet i blod DK1236711T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/702,947 US5122539A (en) 1990-02-12 1991-05-20 Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US07/885,721 US5248785A (en) 1990-02-12 1992-05-18 Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
EP92912561A EP0585366B1 (en) 1991-05-20 1992-05-19 Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood

Publications (1)

Publication Number Publication Date
DK1236711T3 true DK1236711T3 (da) 2004-08-16

Family

ID=27107045

Family Applications (2)

Application Number Title Priority Date Filing Date
DK92912561T DK0585366T3 (da) 1991-05-20 1992-05-19 Anvendelse af allosteriske hæmoglobinmodifikatorer til reducering af oxygenaffinitet i blod
DK02012781T DK1236711T3 (da) 1991-05-20 1992-05-19 Anvendelse af allosteriske hæmoglobinmodifikatiorer til reducering af oxygenaffinitet i blod

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK92912561T DK0585366T3 (da) 1991-05-20 1992-05-19 Anvendelse af allosteriske hæmoglobinmodifikatorer til reducering af oxygenaffinitet i blod

Country Status (9)

Country Link
US (1) US5248785A (da)
EP (3) EP1236711B1 (da)
JP (1) JP3023423B2 (da)
AT (2) ATE265208T1 (da)
CA (1) CA2109575C (da)
DE (2) DE69233320D1 (da)
DK (2) DK0585366T3 (da)
ES (2) ES2220857T3 (da)
WO (1) WO1992020335A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432191A (en) * 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5705521A (en) * 1990-02-12 1998-01-06 The Center For Innovative Technology Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
US5677330A (en) * 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
WO1996032130A1 (en) * 1995-04-10 1996-10-17 Baxter International Inc. The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
US5733869A (en) * 1995-10-06 1998-03-31 Baxter International, Inc. Therapeutic administration of hemoglobin in cardiac arrest
WO1997034594A2 (en) * 1996-03-21 1997-09-25 Dana-Farber Cancer Institute Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases
WO1999038498A1 (en) * 1998-01-28 1999-08-05 Warner-Lambert Company Method for treating alzheimer's disease
EP1206442A4 (en) * 1999-08-24 2004-12-29 Univ Virginia Commonwealth CHIRAL ALLOSTERIC MODIFIERS OF HEMOGLOBIN
AU6912500A (en) * 1999-08-25 2001-03-19 Gmp Companies, Inc. Enhanced oxygen delivery in mammals, methods and reagents related thereto
DE10031741A1 (de) * 2000-06-29 2002-01-17 Sanguibio Tech Ag Einen Sauerstoffträger, ausgewählt aus Hämoglobin oder Hämoglobin- und Myoglobin-enthaltende Zubereitung als Externum zur natürlichen Regeneration der Haut bei Sauerstoff-Mangel
AU2002222552A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
WO2002068930A2 (en) * 2001-02-23 2002-09-06 Allos Therapeutics, Inc. Methods and reagents to acquire mri signals and images
US20030232887A1 (en) * 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
AU2003237215A1 (en) * 2002-05-21 2003-12-12 Allos Therapeutics, Inc. Device for using patient blood or blood fractions as diluent in administering pharmaceuticals
AU2005234788A1 (en) * 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
US20070259966A1 (en) * 2004-04-22 2007-11-08 Allos Therapeutics, Inc. Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
CA2563752A1 (en) * 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Compositions of allosteric hemoglobin modifiers and methods of making the same
CN1997619B (zh) * 2004-07-01 2010-08-25 霍夫曼-拉罗奇有限公司 包含乙炔基的苯基衍生物
JPWO2007123126A1 (ja) * 2006-04-17 2009-09-03 財団法人大阪産業振興機構 慢性心不全における運動耐容能低下の改善剤
BRPI0705396B1 (pt) * 2007-12-12 2021-10-05 Universidade Estadual De Campinas - Unicamp Compostos derivados ftalimídicos
WO2015100235A1 (en) 2013-12-27 2015-07-02 Virginia Commonwealth University Allosteric hemoglobin modifiers with nitric oxide releasing moiety

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2149070C3 (de) * 1971-10-01 1978-03-23 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel
DE2432560A1 (de) * 1974-07-06 1976-01-22 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
DE2541342A1 (de) * 1975-09-17 1977-03-31 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeuren und verfahren zur herstellung derselben
DE2546996C2 (de) * 1975-10-21 1984-07-05 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäure-Derivate, Verfahren zur Herstellung derselben sowie Arzneimittel, die diese Verbindungen als Wirkstoff enthalten
US4704402A (en) * 1982-06-12 1987-11-03 University Of Pittsburgh Method of treating sickle cell anemia
US4887995A (en) * 1985-01-22 1989-12-19 University Of Pittsburgh Method of treating sickle cell anemia
US4699926A (en) * 1986-04-04 1987-10-13 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4751244A (en) * 1986-04-04 1988-06-14 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731381A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Method of treating a person for sickle cell anemia
US4731473A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US5049695A (en) * 1990-02-12 1991-09-17 Center For Innovative Technology Allosteric hemoglobin modifiers
US5122539A (en) * 1990-02-12 1992-06-16 Center For Innovative Technology Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood

Also Published As

Publication number Publication date
EP0585366A1 (en) 1994-03-09
CA2109575C (en) 2000-02-01
ATE265208T1 (de) 2004-05-15
ES2223042T3 (es) 2005-02-16
ES2220857T3 (es) 2004-12-16
EP1236711B1 (en) 2004-03-03
DE69233348T2 (de) 2005-05-12
EP0585366B1 (en) 2004-04-28
EP1468680A2 (en) 2004-10-20
ATE260886T1 (de) 2004-03-15
EP1236711A2 (en) 2002-09-04
DK0585366T3 (da) 2004-08-09
EP1236711A3 (en) 2002-09-18
DE69233320D1 (de) 2004-04-08
JP3023423B2 (ja) 2000-03-21
EP1468680A3 (en) 2005-04-13
DE69233348D1 (de) 2004-06-03
US5248785A (en) 1993-09-28
EP0585366A4 (en) 1994-03-17
CA2109575A1 (en) 1992-11-26
WO1992020335A1 (en) 1992-11-26
JPH07508973A (ja) 1995-10-05

Similar Documents

Publication Publication Date Title
DK0585366T3 (da) Anvendelse af allosteriske hæmoglobinmodifikatorer til reducering af oxygenaffinitet i blod
ATE117805T1 (de) Stabile hämoglobinreferenzlösung.
ATE132751T1 (de) Mittel zur transdermalen applikation enthaltend gestoden
ATE314393T1 (de) Verzögerte freigabe von insulinotropin (glp-1)
DE3583799D1 (de) Feste zubereitung mit langsamer freisetzung.
DK1140148T3 (da) Lagerholdbar formulering af glucagon-agtigt peptid-1
GB2320431A8 (en) N-acetyl cysteine for the treatment of chronic wounds
DK0627161T3 (da) Anvendelse af L-carnitin og alkanoyl L-carnitiner til opbevaring af blod til trandfusioner og stabiliserende opløsninger in
DK261490D0 (da) New pharmaceutical compound
NO931956D0 (no) Imidoesterkryssbundne hemoglobinpreparater
ATE95421T1 (de) Piroxicam enthaltende pharmazeutische zusammensetzung zur topischen anwendung.
DE2961320D1 (en) Hair treatment composition and method
ATE34661T1 (de) Verbindungen zur verminderung des lipidspiegels.
ATE207357T1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis
SE9803902D0 (sv) Sjukvårdsvagn
ES2101000T3 (es) Uso de bmy 14802 en el tratamiento de la ansiedad en pacientes con sindrome de abstinencia de benzodiazepinas.
吉沢榮敏 et al. PTA
SE8006795L (sv) Sjukvardsmobel
SE8800084D0 (sv) Upphengningsanordning
SE8703526L (sv) Oegonmask
IT8784146A0 (it) Procedimento per la realizzazione di portaritratti, in particolareper impiego funerario, e portaritratti ottenuto con il procedimento.
JPS6034243U (ja) 下駄箱